Marpai adds proven diabetes leader to its Proactive Targeted Health Interventions service to improve outcomes for health plan members with diabetes
NEW YORK, Nov. 16, 2022 /PRNewswire/ — Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an AI-technology company transforming self-funded employer health plans, announces the addition of Virta Health as a Premium Health Partner to improve health outcomes for health plan members with diabetes. Virta offers a breakthrough approach that has proven to reverse type 2 diabetes and other chronic metabolic diseases safely and sustainably and without the risks, costs, or side effects of medications or surgery.
According to the CDC, nearly 133 million Americans live with either diabetes or prediabetes and the number is growing. An estimated 37.3 million have diabetes (11.3% of Americans) and 96 million age 18+ have prediabetes (38% of adult U.S. population). The vast majority have type 2 diabetes.
“Diabetes is a highly prevalent, costly condition across our member populations. It represents a disproportionately high amount of health plan costs and is a top priority to address for our clients,” says Marpai CEO, Edmundo Gonzalez. He adds, “Virta is a proven, high impact solution that effectively helps people lower their blood sugar and lose weight while also often reducing or even eliminating the need for medications, including insulin.”
Under its universal Marpai Cares offering for self-funded health plans, Marpai delivers Proactive Targeted Health Interventions aimed at improving health outcomes and trajectories for at-risk health plan members. Using advanced AI, Marpai identifies at-risk members with a high potential for engaging clinical treatment, and matches them to a proven, clinical solution. After rigorous analysis by Marpai data scientists and clinicians, Virta has been selected as the clinical solution for treating diabetes.
“Marpai is focused on driving better member health, which also lowers costs for employers. That is 100% aligned with how Virta works,” says Kevin Kumler, President at Virta Health. “Through this partnership, we intend to bring diabetes reversal to Marpai’s clients and members nationwide, helping them get off of medications and lose weight, while saving money.”
Virta is available within Marpai’s Proactive Targeted Health Intervention feature to all current Marpai members upon renewal and all new members to Marpai after 1/1/2023.
For more information visit, or for investors
About Marpai, Inc.
Marpai, Inc. (Nasdaq: MRAI) is a technology company bringing AI-powered health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA (Third Party Administrator) sector serving self-funded employer health plans representing over $1 trillion in annual claims, Marpai creates the healthiest member population with the greatest cost efficiency within the health plan budget. Marpai leverages AI and big data to proactively fill gaps in care, proactively implement clinical interventions to improve near-term outcomes, and guide members to high-value in-network providers and pharmacy solutions. Operating nationwide, Marpai offers access to provider networks including Aetna and Cigna and delivers all standard TPA services. For more information, visit
About Virta Health
Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes. To learn more about how Virta is transforming lives by reversing type 2 diabetes and other chronic diseases, visit or follow us on Twitter @virtahealth.
Forward-Looking Statement Disclaimer 
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding revenues, employee lives and cash. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,” “may,” “can,” “could”, “will”, “potential”, “should,” “goal” and variations of these words or similar expressions. For example, the Company is using forward looking statements when it discusses the expected benefits to be derived by clients using its solution, the benefits that may be derived from the Virta solution. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai’s current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai’s current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise. More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai’s filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC’s web site at
View original content:
Related Quotes
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k
Uber Health expanding access to rides for patients in employer-sponsored plan market.
The faster people are diagnosed, the better the chance that medical intervention can help stave off the progression.
Cordani's dedication to his personal health starts with an hourlong workout every morning, no matter where in the world he happens to be.
The company earlier this month said it was looking at "strategic alternatives," including a sale in whole or in part.
The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.
Fever among vaccinated COVID patients is becoming more rare, a new study in the U.S. and U.K. found. But that wasn’t the case for recent COVID patients in India.
Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.
National Institute for Health and Care Excellence (NICE) has recommended stopping using five COVID-19 treatments, including Merck & Co Inc's (NYSE: MRK) antiviral pill for high-risk patients, citing cost-effectiveness concerns. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (NASDAQ: GILD) hospital-administered antiviral remdesivir are effective at treating COVID-19, not found to be cost-effective. It also recommended against three other COVID treatme
Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.
By this point in the long slog of the pandemic, many people know the telltale symptoms of a COVID-19 infection: a ragged ache in your throat, a pernicious cough, congestion, fever and full-body exhaustion. But a tiny subset of people also develop less common symptoms, ones that can sound like hexes from a children’s story: hairy tongues, purple toes, welts that sprout on their faces. “Every infectious disease has common and uncommon manifestations,” said Dr. Mark Mulligan, an infectious disease
The FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The FDA-approved ADC for platinum-resistant disease covers patients with one to three prior systemic treatment regimens. ELAHERE was approved under the FDA's accelerated approval program based on objective response rate (ORR) and duration of response (DOR) dat
Amazon continues to add new service offerings to meet the needs of its customers. The online retailer's newly introduced Amazon Clinic will offer affordable virtual healthcare solutions to people in 32 states. There may come a time when you need prompt care for a common health issue and can't get an appointment with your regular doctor.
One of the scariest things about colon cancer is how easy it is to miss some of the symptoms. But early diagnosis is key to combating the disease. "Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in the United States," reports the American Cancer Society (ACS)—which notes that "The rate of people being diagnosed with colon or rectal cancer each year has dropped overall since the mid-1980s, mainly because more people are getting screened and changing their life
With the arrival of cold and flu season, and COVID-19 still infecting and killing thousands weekly, many hospitals have been straining to keep up with demand.
Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.
Is Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has decided to focus its resources on FLT201 in Gaucher disease and FLT190 in Fabry disease. The company will stop investment in further development of FLT180a without a partner. Additionally, Freeline announced updated data from the two patients treated in the first cohort from the MARVEL-1 Phase 1/2 trial of FLT190 at a dose of 7.5e11 vg/kg. People with classic Fabry disease have little to no functional α-Gal A enzyme. Data exhibited elevated α
Lanarkshire nail technician Janice Cassidy Adair, 46, was excited about birth of grandchild
Oracle (ORCL) Cerner partners with life sciences company Labcorp to manage hospital-based laboratories in 10 states.


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *